Androgen receptor modulators and methods for their use
Targeting the N-terminal domain of the androgen receptor with specific compounds addresses the limitations of existing AR therapies by inhibiting AR function and overcoming resistance mechanisms, providing effective treatment for prostate and other cancers.
Patent Information
- Application Number
- PCT/US2024/027412
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-03
- Filing Date
- 2024-05-02
- Publication Date
- 2024-11-07
AI Technical Summary
Current androgen receptor (AR) targeting agents primarily focus on the ligand-binding domain (LBD), which becomes ineffective due to point mutations, gene rearrangements, and the development of constitutively active AR structural variants like AR-V7, leading to resistance in prostate cancer treatment.
Development of compounds targeting the N-terminal domain (NTD) of the androgen receptor, such as those with specific chemical formulas (I) and (II), which can inhibit AR function and mitigate resistance mechanisms by targeting NTD, including AR-V7 variants.
These compounds effectively inhibit AR activity across all stages of prostate cancer, including castration-resistant prostate cancer, and can be used in combination with other therapeutic agents to treat prostate, breast, and ovarian cancers.
Smart Images

Figure IMGF000004_0001 
Figure IMGF000012_0001 
Figure IMGF000013_0001
Abstract
Description
ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USECROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims a benefit of, and priority to, US Provisional Patent Application No 63 / 499,831, filed May 3rd, 2023, the disclosure of which is incorporated by reference in its entirety.TECHNICAL FIELD
[0002] Embodiments of the present invention generally relate to androgen receptor modulators, and more particularly to N-terminal domain androgen receptor inhibitors.BACKGROUND
[0003] Androgens mediate their effects through the androgen receptor (AR). Androgens play a role in a wide range of developmental and physiological responses and are involved in male sexual differentiation, maintenance of spermatogenesis, and male gonadotropin regulation. The androgen receptor (AR) is encoded by the NR3C4 gene and is within the nuclear receptor family. The binding of AR to its endogenous ligand 5 a- dihydrotestosterone (DHT) and testosterone is responsible for starting male sexual development and differentiation. Testosterone is synthesized by the Leydig cells in the testes and circulates mostly bound to the serum sex hormone -binding globulin (SHBG) and albumin. The free form enters prostate cells, where testosterone is converted to the more potent form of DHT, which promotes growth and survival of prostate cells. High affinity binding of DHT to AR displaces other AR-bound proteins and drives the AR complex to the nucleus where it dimerizes and binds to androgen response elements (AREs) in the promoter region of target genes. The full-length AR protein has three major domains, the N-terminal domain (NTD), the DNA-binding domain (DBD), and the ligand-binding domain (LBD). All three are required for the proper regulation and function of AR. The AR can be activated in the absence of testicular androgens by alternative signaltransduction pathways in castration-resistant disease, which is consistent with the finding that nuclear AR protein is present in secondary prostate cancer tumors.
[0004] Prostate cancer is one of the most common male malignancies and is the second leading cause of cancer deaths among males in the United States. The current standard of care is androgen deprivation therapy, which is initially effective for the treatment of metastatic prostate cancer, but most patients develop castration-resistant prostate cancer (CRPC) that can further develop into metastatic CRPC (mCRPC).
[0005] Current AR targeting agents available for treatment primarily target the LBD of AR. However, point mutations, gene rearrangements resulting in overexpression of AR, development of constitutively active AR structural variants, and several other mechanisms may render AR-LBD targeting inhibitors ineffective. Multiple mechanisms may lead to resistance in prostate cancer cells, one of them being increased production of short AR splice variants. The most prominent variants in prostate and breast cancer are ARV7 and ARV567es.
[0006] Constitutively active AR structural variants (without LBD), of which AR splice variant-7 (AR-V7) is the most frequently detected, are considered a potential driver of castration-resistant prostate cancer (CRPC). AR-V7 is expressed in over 80% of CRPC patient samples in Stand Up to Cancer (SU2C) prostate cancer cohort. AR-V7 can dimerize without the presence of the receptor-ligand and drive AR response genes transcription in the nucleus, this provides them with the ability to drive prostate cancer even in the absence of LBD. ARV7 displays noncanonical nuclear import kinetics and short chromatin residence time as compared to ARFL. Further, in-vitro and in-vivo studies have shown that AR-V7 can drive prostate cancer and its inhibition leads to tumor growth control and induces tumor regression.
[0007] The AR pathway has also been implicated in breast cancer and may be a suitable target for triple-negative breast cancer (TNBC) where AR plays a role in the proliferation of breast cancer cells by either promoting proliferation or inhibitingproliferation depending on the expression of estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2), as well as ovarian cancers. Up to 90% of breast cancer have AR expression and AR-V7 has been detected in primary breast cancer samples and cell lines.
[0008] Therefore, it is desirable to target domains other than LBD as a potential path for treating cancers such as prostate, breast, and ovarian cancers.SUMMARY
[0009] The following summary is illustrative only and is not intended to be in any way limiting. In addition to the illustrative aspects, example embodiments, and features described, further aspects, example embodiments, and features will become apparent by reference to the following detailed description.
[0010] In some aspects of the present invention, a compound having formula (I) or(II) or a pharmaceutically acceptable salt thereof is presented:wherein doted line “- is a single bond or a double bond;“n” is an integer from 0 to 5; “p” is an integer from 0 to 4;A is a C3-C9 cycloalkyl group, a C3-C12heterocycloalkyl group, a C6-C12 aryl group, or a C3-C12 heteroaryl group;X1, X3, X4and X5are independently at each occurrence nitrogen, NH, CH or CH2;X2is independently at each occurrence carbon or nitrogen; wherein in formula (I) at least one of X1, X2, X3, X4and X5is carbon, CH or CH2 and at least two of X1, X2, X3, X4and X5are nitrogen or NH, and in formula (II) at least two of X1, X2, X3, X4and X5are nitrogen or NH;Y is O, S, or NR6;R1is a C1-C6alkyl group optionally substituted with one or more fluorine or deuterium or a C3-C7cycloalkyl group optionally substituted with one or more fluorine or deuterium;R2is a C1-C6alkyl group optionally substituted with one or more fluorine, a C3-C7cycloalkyl group optionally substituted with one or more fluorine, — OR7, or SF5;R3is independently at each occurrence halogen, — CN, — OR7, — NHC(=O)R7, — C(- C6H5)R7R8, C(=O)NR7R8, NR7R8, P(=O)R7R8, a Ci-C6alkyl group optionally substituted with one or more fluorine or deuterium, a C3-C7cycloalkyl group optionally substituted with one or more fluorine or deuterium, a C1-C12heterocycloalkyl group optionally substituted with one or more R9, or a C1-C12heteroaryl group optionally substituted with one or more R9;R4is independently at each occurrence halogen, — CN, — OR7, — NHC(=O)R7, — C(=O)NR7R8, — NR7R8, — P(=O)R7R8, a C1-C6alkyl group optionally substituted with one or more fluorine or deuterium, or a C3-C7cycloalkyl group optionally substituted with one or more fluorine or deuterium;R5is a C1-C12heterocycloalkyl group or a C1-C12heteroaryl group optionally substituted with one or more R9;R6is hydrogen, a C1-C6alkyl group, or a C3-C7cycloalkyl group;R7and R8are independently at each occurrence hydrogen, a C1-C6alkyl group optionally substituted with one or more fluorine or an aminoalkyl group, a Ce-Cio aryl group optionally substituted with one or more fluorine, or R7and R8together with the carbon or nitrogen to which each is attached form a C3-C7cycloalkyl group optionally substituted with one or more fluorine or a C3-C15 heterocycloalkyl group optionally substituted with one or more fluorine; andR9is independently at each occurrence halogen, — CN, — OR7, — NHC(=O)R7, — C(=O)NR7R8, NR7R8, a C1-C6alkyl group optionally substituted with one or more fluorine or a C3-C7cycloalkyl group optionally substituted with one or more fluorine; with the proviso that if in formula (I), A is a Ce-Cnaryl group, Y is NH, X1, X2, X3and X4, are all nitrogen, R1is a C1-C6alkyl group, R2is a C1-C6alkyl group optionally substituted with one or more fluorine, n is i, then R3is not a halogen.
[0011] In some aspects of the present invention, a pharmaceutical composition is presented. The pharmaceutical composition includes a compound having a formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, or co-crystal thereof, and a pharmaceutically carrier, diluent, or excipient.
[0012] In some aspects of the present invention, a method for modulation of androgen receptor activity for treatment of prostate cancer, breast cancer, ovarian cancer, or melanoma is presented. The method includes administering to a patient a therapeutically effective amount of a pharmaceutical composition including a compound of formula (I).DETAILED DESCRIPTION OF EXAMPLE EMBODIMENTS
[0013] Various example embodiments will now be described more fully with reference to the accompanying drawings in which only some example embodiments are shown. Specific structural and functional details disclosed herein are merely representative for purposes of describing example embodiments. Example embodiments, however, may be embodied in many alternate forms and should not be construed as limited to only the example embodiments set forth herein. On the contrary, example embodiments are tocover all modifications, equivalents, and alternatives thereof.
[0014] The terminology used herein is for the purpose of describing particular example embodiments only and is not intended to be limiting. Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which example embodiments belong. It will be further understood that terms, e.g., those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.
[0015] As used herein, the singular forms “a,” “an,” and “the,” are intended to include the plural forms as well, unless the context clearly indicates otherwise. As used herein, the terms “and / or” and “at least one of’ include any and all combinations of one or more of the associated listed items. It will be further understood that the terms “comprises,” “comprising,” “includes,” and / or “including,” when used herein, specify the presence of stated features, integers, steps, operations, elements, and / or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof.
[0016] Approximating language, as used herein throughout the specification and claims, may be applied to modify any quantitative representation that could permissibly vary without resulting in a change in the basic function to which it is related. Accordingly, a value modified by a term such as “about” is not to be limited to the precise value specified. Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
[0017] To more clearly and concisely describe and point out the subject matter of the claimed invention, the following definitions are provided for specific terms that are used in the following description and the claims appended hereto.
[0018] Definitions of specific functional groups and chemical terms are described in more detail below. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed., inside cover, and specific functional groups are generally defined as described therein. Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures including the replacement of hydrogen by deuterium or tritium, the replacement of a carbon by a 13C- or 14C-enriched carbon, or the replacement of a fluorine by 18F-enriched fluorine, are within the scope of this invention. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention.
[0019] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
[0020] Where a particular enantiomer is preferred, it may, in some embodiments be provided substantially free of the corresponding enantiomer, and may also be referred to as “optically enriched.” “Optically-enriched,” as used herein, means that the compound is made up of a significantly greater proportion of one enantiomer. In certain embodiments,the compound is made up of at least about 90% by weight of a preferred enantiomer. In other embodiments, the compound is made up of at least about 95%, 98%, or 99% by weight of a preferred enantiomer. Preferred enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including chiral high-pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts or prepared by asymmetric syntheses.
[0021] As used herein, the term “alkyl group” refers to a saturated monovalent group consisting of a linear or branched array of atoms that is not cyclic. Alkyl groups are defined to include at least one carbon atom and are represented by formula CnH2n+1. The array of atoms included in the alkyl group may be composed exclusively of carbon and hydrogen. By way of example, the term “C1-C10alkyl group” contains at least one but no more than 10 carbon atoms. A methyl group (i.e. CH3 — ) is an example of a monovalent Ci alkyl group. A decyl group (i.e., CH3(CH2)9 — ) is an example of a monovalent C10alkyl group. Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
[0022] As used herein the term “cycloalkyl group” refers to a group having a valence of at least three, and consisting of a saturated or a partially unsaturated array of atoms which is cyclic but which is not aromatic. A “cycloalkyl” may include one or more noncyclic components. For example, a cyclohexylmethyl group (C6H11CH2) is a cycloalkyl group which includes a cyclohexyl ring (the array of atoms which is cyclic but which is not aromatic) and a methylene group (the noncyclic component). Further, a cycloalkyl group may be monocyclic or may include one or more ring systems. By way of example, the term “a C3-C10cycloalkyl group” includes cycloalkyl groups containing at least three but no more than 10 carbon atoms. The cycloalkyl group 2 -tetrahydrofuranyl (C4H7O — ) represents a C4cycloalkyl group. The cyclohexylmethyl group (C6H1 1CH2— ) represents a C7 cycloalkyl group.
[0023] As used herein the term “aryl group” refers to a monovalent aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. Aryl group encompasses 5- and 6-memberedcarbocyclic aromatic rings, for example, benzene; bicyclic ring systems wherein at least one ring is carbocyclic and aromatic, for example, naphthalene, indane, and tetralin; and tricyclic ring systems wherein at least one ring is carbocyclic and aromatic, for example, fluorene.
[0024] The term “aryl group “also encompasses multiple ring systems having at least one carbocyclic aromatic ring fused to at least one carbocyclic aromatic ring, cycloalkyl ring, or heterocycloalkyl ring. For example, aryl group includes 5- and 6- membered carbocyclic aromatic rings fused to a 5- to 7-membered heterocycloalkyl ring containing one or more heteroatoms chosen from N, O, and S. For such fused, bicyclic ring systems wherein only one of the rings is a carbocyclic aromatic ring, the point of attachment may be at the carbocyclic aromatic ring or the heterocycloalkyl ring. Examples of aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene, and the like. In certain embodiments, an aryl group can include from 5 to 20 carbon atoms, and in certain embodiments, from 5 to 12 carbon atoms.
[0025] As used herein, the term “heteroaryl group” refers to a monovalent heteroaromatic radical derived by the removal of one hydrogen atom from a single atom of a parent heteroaromatic ring system. Heteroaryl group encompasses multiple ring systems having at least one aromatic ring fused to at least one other ring, which can be aromatic or non-aromatic in which at least one ring atom is a heteroatom. Heteroaryl group encompasses 5- to 12-membered aromatic, monocyclic rings (such as 5- to 7-membered rings) containing one or more, for example, from 1 to 4, or in certain embodiments, from 1 to 3, heteroatoms chosen from N, O, and S, with the remaining ring atoms being carbon; and bicyclic heterocycloalkyl rings containing one or more, for example, from 1 to 4, or in certain embodiments, from 1 to 3 , heteroatoms chosen fromN, O, and S, with the remainingring atoms being carbon and wherein at least one heteroatom is present in an aromatic ring. For example, heteroaryl includes a 5- to 7-membered heteroaromatic ring fused to a 5- to 7-membered cycloalkyl ring. For such fused, bicyclic heteroaryl ring systems wherein only one of the rings contains one or more heteroatoms, the point of attachment may be at the heteroaromatic ring or the cycloalkyl ring. In certain embodiments, when the total number of N, S, and O atoms in the heteroaryl group exceeds one, the heteroatoms are not adjacent to one another. In certain embodiments, the total number of N, S, and O atoms in the heteroaryl group is not more than two. In certain embodiments, the total number of N, S, and O atoms in the aromatic heterocycle is not more than one. By way of example, the term “C5-C10 heteroaryl group” contains at least 5 but no more than 10 carbon atoms. The heteroaryl group benzoimidazolyl (C7H5N2 — ) represents a C7 heteroaryl group. The pyridyl group (C5H4N — ) represents a C5 heteroaryl group.
[0026] As used herein, the term “heterocycloalkyl group” refers to non-aromatic group having a valence of one which consists of at least one heteroatom selected from the group consisting of nitrogen, oxygen and sulfur. Unless stated otherwise specifically in the specification, the heterocycloalkyl group can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocycloalkyl group can be optionally oxidized; the nitrogen atom can be optionally quatemized; and the heterocycloalkyl group can be partially or fully saturated. By way of example, the term “C4-C7 heterocycloalkyl group” contains at least 4 but no more than 7 carbon atoms. The heterocycloalkyl group dioxyl (C4H7O2 — ) represents a C4 heterocycloalkyl group. The piperidyl group (C5H9N — ) represents a C5 heterocycloalkyl group.
[0027] Examples of heteroaryl and heterocycloalkyl groups include, but are not limited to, groups derived from acridine, arsindole, carbazole, beta-carboline, chromane, chromene, cinnoline, furan, furazan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine,pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like.
[0028] As used herein, the term “therapeutically effective amount” refers to an amount (of a compound) that is sufficient to provide a therapeutic benefit to a patient in the treatment or management of a disease or disorder, or to delay or minimize one or more symptoms associated with the disease or disorder.
[0029] As used herein, the term “pharmaceutically acceptable salt” refers to any salt suitable for administration to a patient. Examples of salts include, but are not limited to, acid-derived, base-derived, organic, inorganic, amine, and alkali or alkaline earth metal salts, including but not limited to calcium salts, magnesium salts, potassium salts, sodium salts, salts of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
[0030] In some embodiments, a compound having formula (I) or (II) or a pharmaceutically acceptable salt thereof is presented:wherein dotted line “ - ” is a single bond or a double bond;“n” is an integer from 0 to 5; “p” is an integer from 0 to 4;A is a C3-C9 cycloalkyl group, a C3-C12 heterocycloalkyl group, a C6-C12 aryl group, or a C3-C12 heteroaryl group;X1, X3, X4and X5are independently at each occurrence nitrogen, NH, CH or CH2;X2is independently at each occurrence carbon or nitrogen; wherein in formula (I) at least one of X1, X2, X3, X4and X5is carbon, CH or CH2 and at least two of X1, X2, X3, X4and X5are nitrogen or NH, and in formula (II) at least two of X1, X2, X3, X4and X5are nitrogen or NH;Y is O, S, or NR6;R1is a C1-C6alkyl group optionally substituted with one or more fluorine or deuterium or a C3-C7cycloalkyl group optionally substituted with one or more fluorine or deuterium;R2is a C1-C6alkyl group optionally substituted with one or more fluorine, a C3-C7cycloalkyl group optionally substituted with one or more fluorine, — OR7, or SF5;R3is independently at each occurrence halogen, — CN, — OR7, — NHC(=O)R7, — C(- C6H5)R7R8, C(=O)NR7R8, NR7R8, P(=O)R7R8, a C1-C6alkyl group optionallysubstituted with one or more fluorine or deuterium, a C3-C7cycloalkyl group optionally substituted with one or more fluorine or deuterium, a C1-C12heterocycloalkyl group optionally substituted with one or more R9, or a C1-C12heteroaryl group optionally substituted with one or more R9;R4is independently at each occurrence halogen, — CN, — OR7, — NHC(=O)R7, — C(=O)NR7R8, — NR7R8, — P(=O)R7R8, a C1-C6alkyl group optionally substituted with one or more fluorine or deuterium, or a C3-C7cycloalkyl group optionally substituted with one or more fluorine or deuterium;R5is a C1-C12heterocycloalkyl group or a C1-C12heteroaryl group optionally substituted with one or more R9;R6is hydrogen, a C1-C6alkyl group, or a C3-C7cycloalkyl group;R7and R8are independently at each occurrence hydrogen, a C1-C6alkyl group optionally substituted with one or more fluorine or an aminoalkyl group, a Ce-Cio aryl group optionally substituted with one or more fluorine, or R7and R8together with the carbon or nitrogen to which each is attached form a C3-C7cycloalkyl group optionally substituted with one or more fluorine or a C3-C15 heterocycloalkyl group optionally substituted with one or more fluorine; andR9is independently at each occurrence halogen, — CN, — OR7, — NHC(=O)R7, — C(=O)NR7R8, NR7R8, a C1-C6alkyl group optionally substituted with one or more fluorine or a C3-C7cycloalkyl group optionally substituted with one or more fluorine; with the proviso that if in formula (I), A is a group, Y is NH, X1, X2, X3and X4,are all nitrogen, R1is a C1-C6alkyl group, R2is a C1-C6alkyl group optionally substituted with one or more fluorine, n is 1, then R3is not a halogen.Series A
[0031] In some embodiments, the compound has formula (I) and is selected fromthe group consisting of:and any pharmaceutically acceptable salts thereof.
[0032] In some embodiments, the compound has formula (III) to (XX), wherein Y is O, S, or NR6, R1is a C1-C3 alkyl group optionally substituted with one or more fluorine, R2is a C1-C3 alkyl group substituted with one or more fluorine, and R6is hydrogen, a Ci- Ce alkyl group, or a C3-C7cycloalkyl group.
[0033] In some embodiments, the compound has formula (III) to (XX), wherein Y is O, S, or NR6, R1is a C1-C3 alkyl group optionally substituted with one or more fluorine, R2is a C1-C3 alkyl group substituted with one or more fluorine, R3is independently at each occurrence halogen, — CN, — OR7, or a C1-C3 alkyl group substituted with one or more fluorine, and R6is hydrogen, a C1-C6alkyl group, or a C3-C7cycloalkyl group.
[0034] In some embodiments, the compound has formula (III) to (XX), wherein Y is O, S, or NR6, R1is a C1-C3 alkyl group optionally substituted with one or more fluorine, R2is a C1-C3 alkyl group substituted with one or more fluorine, R3is independently at each occurrence a C1-C3 alkyl group substituted with one or more fluorine, and R6is hydrogen, a C1-C6alkyl group, or a C3-C7cycloalkyl group.
[0035] In some embodiments, the compound has formula (III) to (XX), wherein Y is NR6, R1is a C1-C3 alkyl group optionally substituted with one or more fluorine, R2is a C1-C3 alkyl group substituted with one or more fluorine, R3is independently at each occurrence a C1-C3 alkyl group substituted with one or more fluorine, and R6is a C1-C3 alkyl group.
[0036] Non-limiting examples of compounds having a formula (I) include:Series B
[0037] In some embodiments, the compound has a formula (XXI) or any pharmaceutically acceptable salt thereof:(XXI)wherein “n” is an integer from 1 to 5, and at least one R3is a C1-C12heterocycloalkyl group optionally substituted with one or more R9or a C1-C12heteroaryl group optionally substituted with one or more R9.
[0038] In some embodiments, the compound has a formula (XXI) and is selected from the group consisting of:pharmaceutically acceptable salts thereof, wherein “q” is an integer from 0 to 4; “r” is an integer from 0 to 4, and “s” is an integer from 0 to 3.
[0039] In some embodiments, the compound has formula (XXII) to (XXIV), and R1is a C1-C3 alkyl group optionally substituted with one or more fluorine, R2is a C1-C3 alkyl group substituted with one or more fluorine, and R6is hydrogen.
[0040] Non-limiting examples of compounds having a formula (XXI) include:Series C
[0041] In some embodiments, the compound has formula (II) and is selected from the group consisting of:S3and anypharmaceutically acceptable salts thereof.
[0042] In some embodiments, the compound has formula (XXV) to (XXXIX), and R5is selected from the group consisting of:wherein R9is halogen or a C1-C3 alkyl group optionally substituted with one or more fluorine.
[0043] In some embodiments, the compound has formula (XXV) to (XXXIX), Y is O, S, or NR6, R1is a C1-C3 alkyl group optionally substituted with one or more fluorine, R4is independently at each occurrence halogen, and R6is hydrogen, a C1-C6alkyl group, or a C3-C7cycloalkyl group.
[0044] In some embodiments, the compound has formula (XXV) to (XXXIX), Y is NR6, R1is a C1-C3 alkyl group optionally substituted with one or more fluorine, R4is independently at each occurrence halogen, and R6is a C1-C3 alkyl group.
[0045] Non-limiting examples of compounds having a formula (II) include:and any pharmaceutically acceptable salts thereof.
[0046] In some embodiments, the compound of the present invention is an optically enriched R-isomer. In some embodiments, the compound of the present invention is an optically enriched S -isomer. In some embodiments, the compound of the present invention is a mixture of R and S-isomers.
[0047] Without being bound by any theory it is believed that, in some embodiments, compounds of the present invention may be capable of targeting NTD of AR. As noted earlier, targeting NTD of AR may facilitate inhibition of AR function and also mitigate the current drug resistance mechanisms that may develop post androgendeprivation or LBD inhibitor treatment. Further, targeting NTD may mitigate variant and LBD point mutation driven resistance thereby providing effective treatment against all stages of AR driven prostate cancer.
[0048] In some embodiments, the compounds of the present description may be capable of targeting NTD of ARV7. ARV7 may include NTD, DBD and a cryptic exon. NTD of ARV7 may include Taul, Tau5 and a FXXLF motif. In some embodiments, the compounds of the present description may be capable of targeting FXXLF motif of ARV7.
[0049] In some embodiments, a pharmaceutical composition is presented. The pharmaceutical composition includes a compound as described herein above or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, or co-crystal thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. In some embodiments, thepharmaceutical composition includes a compound having a formula (I) to (XXXIX). The pharmaceutical composition may further one or more other additional anticancer therapeutic agents in some embodiments.
[0050] The pharmaceutical compositions of the present invention may be in any form that allows for the composition to be administered to a subject. For example, the composition may be in the form of a solid, liquid, or gas (aerosol). Pharmaceutical compositions may be formulated to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a subject. To further optimize the pharmacokinetic profile of the compounds of the present invention, the compounds may be administered in conjunction with a suitable delivery vehicle (e.g., microcapsules, microspheres, biodegradable polymer films, lipid-based delivery systems such as liposomes and lipid foams, viscous instillates and absorbable mechanical barriers) useful for maintaining the necessary concentrations of the prodrugs or the therapeutic agent at the site of the disease.
[0051] A process for preparing a pharmaceutical composition is also presented. The process includes mixing a compound as described herein above or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, or co-crystal thereof with a pharmaceutically acceptable carrier, diluent, or excipient. In some embodiments, the process includes mixing a compound having a formula (I) to (XXXIX) or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, or co-crystal thereof with a pharmaceutically acceptable carrier, diluent, or excipient.
[0052] In some embodiments, methods of treating or reducing symptoms of a certain disease by administering a compound of the present invention are also presented. The compounds or derivatives thereof can be administered to any host, including a human, a non-human animal, and mammals, in an amount effective to treat a disorder. In some embodiments, methods of treating or reducing symptoms of a certain disease by administering a compound having a formula (I) to (XXXIX) is presented.
[0053] In some embodiments, the compounds of the present description may be used as single agents or in combination with other additional anticancer therapeutic agents for treating metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, non-metastatic castration-sensitive prostate cancer, localized prostate cancer or metastatic / non-metastatic castration-resistant prostate cancer that exhibits intrinsic or acquired resistance to enzalutamide, abiraterone acetate or any other androgen signaling axis / receptor inhibitors.
[0054] In some embodiments, the compounds of the present description may be used as single agents or in combination with other additional anticancer therapeutic agents for treating AR-positive HER2 positive metastatic, advanced breast cancer, AR-positive advanced TNBC, ER-negative HER2 positive (ER-HER2+) breast cancer, or ER-positive HER2 negative (ER+HER2-) breast cancer that exhibit poor therapeutic efficacy against known ER antagonists.
[0055] In some embodiments, the compounds of the present description may be used as single agents or in combination with other additional anticancer therapeutic agents for treating ovarian cancer. In some embodiments, the compounds of the present description may be used as single agents or in combination with other additional anticancer therapeutic agents for treating BRAF / MEK targeted therapy resistant melanoma.
[0056] In some embodiments, the compounds of the present description may be used as single agents or in combination with other additional AR antagonists or AR LBD inhibitors. Non-limiting examples of other additional AR antagonists or AR LBD inhibitors include bicalutamide, enzalutamide, flutamide, nilutamide, apalutamide, darolutmide, proxalutamide, or combinations thereof. In some embodiments, the compounds of the present invention may be used in combination with docetaxel, olaparib, talazoparib (PARP inhibitors), selumetinib, capivasertib (AKT inhibitors), ribociclib (CDK inhibitor), BET inhibitors, or combinations thereof.
[0057] In some embodiments, the compounds of the present description may beused as single agents or in combination with other antibody -radioligand conjugate, immune check point therapy like pembrolizumab, cell therapy like prostate targeting CART-T cell, prostate targeting bi-specific antibodies and combinations thereof.
[0058] In some embodiments, a method of treating prostate cancer, breast cancer ovarian cancer, or melanoma is presented. In some embodiments, a method of treating prostate cancer is presented. Non-limiting examples of prostate cancer include metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, non- metastatic castration-resistant prostate cancer, non-metastatic castration-sensitive prostate cancer, localized prostate cancer or metastatic / non-metastatic castration resistant prostate cancer that exhibits intrinsic or acquired resistance to enzalutamide, abiraterone acetate or any other androgen signalling axis / receptor inhibitors. Non-limiting examples of breast cancer include AR positive HER2 positive metastatic, advanced breast cancer, AR positive advanced TNBC, ER negative HER2 positive (ER-HER2+) breast cancer, and ER positive HER2 negative (ER+HER2-) breast cancer that exhibit poor therapeutic efficacy against known ER antagonists. Non-limiting example of melanoma includes BRAF / MEK targeted therapy resistant melanoma.
[0059] The method includes administering to a patient an effective amount of a pharmaceutical composition including a compound of the present invention or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, or co-crystal thereof. The pharmaceutical composition may further one or more other additional anticancer therapeutic agents in some embodiments.
[0060] The pharmaceutical composition may be administered by any suitable method known to a person skilled in the art. Typical routes of administration include, without limitation, oral, topical, parenteral, sublingual, rectal, vaginal, ocular, and intranasal. The term parenteral as used herein includes intravenous, intraperitoneal, intramuscular, intradermal, and epidermal including subcutaneous and intradermal, oral, or application to mucosal surfaces, e.g, by intranasal administration using inhalation of aerosol suspensions, and by implanting to muscle or other tissue in the subject.EXAMPLESGeneral methods for synthesisSynthesis of compounds of Series A
[0061] Example 1: Synthesis of (S)-N-(l-(4-fhiorophenyl)ethyl)-7-(trifluoromethyl)imidazo[l,5-b]pyridazin-2-amine (Compound 1)
[0062] Step 1 : Synthesis of 2,2, 2-trifluoro-N-((6-oxo- 1,4,5, 6-tetrahydropyridazin- 3-yl)methyl)acetamide
[0063] A stirred solution of 6-(aminomethyl)-4,5-dihydropyridazin-3(2H)-one (2.0 g, 15.7 mmol) in acetonitrile (20 mL), TFAA (3.3 mL, 23.5 mmol ) and TEA (4.4 mL, 31.4 mmol) was stirred at rt. After 48h the reaction mass was diluted with water and the product was extracted into 10% MeOH in DCM, dried over sodium sulfate and concentrated under reduced pressure to obtain a crude product which was purified by column chromatography to give 2,2,2-trifluoro-N-((6-oxo-l,4,5,6-tetrahydropyridazin-3-yl)methyl)acetamide as a yellow solid (1.4g, 34%).
[0064] Step 2: Synthesis of 2,2,2-trifhioro-N-((6-oxo-l,6-dihydropyridazin-3- yl)methyl)acetamide
[0065] The product of Step 1 (1.0 g, 4.48 mmol) in acetic acid (10 mL), bromine (0.23 mL, 4.48 mmol) and TEA (4.4 mL, 31.4 mmol) was heated at 50°C for 16h. Thereaction mixture was evaporated to dryness and the product was extracted into ethyl acetate, washed with saturated sodium bicarbonate solution, dried over sodium sulfate and concentrated under reduced pressure to give 2,2,2-trifluoro-N-((6-oxo-l,6- dihydropyridazin-3-yl)methyl)acetamide as a yellow solid (700mg, 71%) which was used directly for the next step without further purification.
[0066] Step 3: Synthesis of 2-chloro-7-(trifluoromethyl)imidazo[l,5-b]pyridazine
[0067] A stirred solution of the product of Step 2 (700 mg, 3.16 mmol) in sulpholane (10 mL) and POC13 (2.36 mL, 25.3 mmol) was heated at 100~°C for 16h. The reaction mixture was evaporated to dryness and the product was extracted into ethyl acetate, washed with saturated sodium bicarbonate solution, dried over sodium sulfate and concentrated under reduced pressure to give a crude product which was purified by column chromatography to give 2-chloro-7-(trifluoromethyl)imidazo[l,5-b]pyridazine as a yellow solid (380 mg, 54%).
[0068] Step 4: Synthesis of(S)-N-(l-(4-fhiorophenyl)ethyl)-7-(trifluoromethyl)imidazo[ 1 ,5 -b]pyridazin-2-amine.
[0069] A mixture of the product of step 3 (150mg, 0.67mM) in DMA (5 mL), potassium carbonate (280 mg, 0.67 mmol) and (S)- 1 -(4-fluorophenyl)ethan- 1 -amine (94.2 mg, 0.67 mmol) was heated at 80°C for 16 h. The reaction mixture was diluted with ice water and the product was extracted into ethyl acetate. This extract was dried over sodium sulfate, filtered, concentrated under reduced pressure and purified by prep reverse chromatography to give (S)-N-(l-(4-fhiorophenyl)ethyl)-7-(trifluoromethyl)imidazo[l,5- b]pyridazin-2-amine as a pale yellow solid (43 mg, 20%).
[0070] 1H - NMR: (400 MHz, DMSO-d6): 5 (ppm) 7.87 (d, J = 6.8 Hz, 1H), 7.84(d, J = 10.00 Hz, 1H), 7.45-7.38 (m, 2H), 7.35 (s, 1H), 7.18-7.09 (m, 2H), 6.55 (d, J = 9.6 Hz, 1H), 4.89-4.81 (m, 1H), 1.48 (d, J = 6.8 Hz, 3H). LCMS: 99.43% (m / z = 325.26 [M+H]+).
[0071] Example 2: Synthesis of (S)-N-(l-(4-fhiorophenyl)ethyl)-3-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyridin-6-amine (Compound 2)Compound 2
[0072] A suspension of 6-bromo-3-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyridine (0.15 g, 0.56 mmol), (S)- 1 -(4-fluorophenyl)ethan- 1 -amine (0.15 mg, 1.12 mmol) and NaOtBu (0.16 g, 1.69 mmol) in toluene (5 mL) in a glass tube was purged with nitrogen gas for 15 minutes. After adding Pd2(dba)3 (25 mg, 0.028 mmol) and racemic BINAP (26 mg, 0.042 mmol) the tube was sealed and the reaction mass was heated at 100°C for 16h. The reaction mixture was cooled, filtered through celite, and concentrated under reduced pressure. The residue was diluted with water (10 mL) and the product extracted into EtOAc, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by column chromatography to give (S)-N-(l-(4- fhiorophenyl)ethyl)-3-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyridin-6-amine (94 mg, 51 %) as an off white solid.
[0073] 1H -NMR (400 MHz, DMSO-d6): 5 (ppm) 7.82 (d, J = 9.60 Hz, 1H), 7.46- 7.42 (m, 2H), 7.33 (dd, J = 9.6 & 1.6 Hz, 1H), 7.18 (t, J = 8.80 Hz, 2H), 6.94 (s, 1H), 6.91 (d, J = 6.00 Hz, 1H), 4.53-4.46 (m, 1H), 1.45 (d, J = 6.80 Hz, 3H). LCMS: 96.5% (m / z = 325.2 [M+H]+).
[0074] Example 3: Synthesis of (R )-A-(l-(pyridin-4-yl)ethyl)-3 -(trifluoromethyl) [l,2,4]triazolo[4,3-b]pyridazin-6-amine (Compound 3)
[0075] To a sealed tube was added trifluoroacetic acid (60 mL) followed by 3- chloro-6-hydrazinopyridazine (11.0 g, 0.049 mol) at 0°C and heated at 100°C for 24 h. The reaction mixture was evaporated to dryness. The crude mass was dissolved in EtOAc and washed with aqueous solution of NaHCO3and the process was repeated for three times. The organic layer was separated, and the aqueous layer was extracted two times with EtOAc. The combined organic layers were then washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain (6-Chloro-3-trifluoromethyl- [l,2,4]triazolo[4,3-b]pyridazine) as an off white solid (11.5 g, 31%).
[0076] Step 1: To the solution of l-(pyridin-4-yl)ethanone (2.0 g, 0.016 mol) and (R )-2-methylpropane-2-sulfinamide (3.9 g, 0.033 mol) in anhydrous THF (20 ml) at 0 °C, was added Ti(OiPr)4 (10.4 ml, 0.033). The reaction was heated at 60 °C for 24 h. The reaction mixture was poured into crushed ice and extracted with DCM. The combined organic layer was washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography, eluted with 50:50 mixture of EtOAc and hexanes providing (R, E)-2-methyl-N-(l-(pyridin-4-yl)ethylidene)propane-2- sulfinamide as a colourless liquid (1.4 g, 38%); Mass: 225 [M+H]+.
[0077] Step 2: To the solution of (R)-2-methyl-N-(l-(pyridin-4- yl)ethylidene)propane-2-sulfinamide (1.4 g, 0.0625 mol) was added DIBAL-H (12.5 ml, 0.0125 mol) at -78 °C and stirred for 6 h. The reaction mixture was quenched with ammonium chloride, poured over crushed ice and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel chromatography, eluted with 5% MeOH in DCM providing (R)-2-methyl-N-((R)-l-(pyridin-4-yl)ethyl)propane-2- sulfinamide as a colourless liquid (0.630 g, 45%);1H-NMR (400 MHz, CDC3): δ (ppm) 8.59 (d, J = 4 Hz, 2H), 7.28 (t, J = 12 Hz, 2H), 4.54-4.51 (m, 1H), 1.52 (d, J = 8 Hz , 3H), 1.25 (s , 9H).
[0078] Step 3: To the solution of (R)-2-methyl-N-((R)-l-(pyridin-4- yl)ethyl)propane-2-sulfinamide (0.6 g, 0.0013 mol) in DCM (20 ml) was added 4M HC1 in dioxane (10 ml) at 0 °C and stirred at RT for overnight. The reaction mixture was concentrated and co-precipitated with MeOH:Ether as co-solvent to provide (R )- 1 - (pyridin-4-yl)ethanamine hydrochloride as a white solid (0.5 g, 93%).
[0079] Step 4: To the solution of (R)-1-(pyridin-4-yl)ethanamine hydrochloride (0.200 g, 0.90 mol) in DMF (10 ml) was added DIPEA (0.313 ml, 0.90 mol) followed by 6-chloro-3-(trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazine (0.100 g, 0.81 mol). The reaction was sealed and heated at 80 °C for 16 h. The reaction mixture was diluted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography, eluted with 5% MeOH in DCM providing (R)-N- (l-(pyridin-4-yl)ethyl)-3-(trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazin-6-amine as an off-white solid (0. 1 g, 20%).
[0080] 1H-NMR (400 MHz, DMSO- d6): 5 (ppm) 8.50 (d, J = 4.4 Hz, 2H), 8.36 (d,J = 6.4 Hz, 1H), 8.11 (d, J = 10 Hz, 1H), 7.37-7.35 (m, 2H), 7.06 (d, J = 10 Hz , 1H), 4.85- 4.78 (m, 1H), 1.50 (d, J = 7.2 Hz, 3H); Mass: 309.31 [M+H]+; LCMS: 96.39%; SOR: [a]:xT= + 194.94.Example 4: Synthesis of Synthesis of (R)-N-(l-(pyridin-3-yl)ethyl)-3-(trifhioromethyl)- [l,2,4]triazolo[4,3-b]pyridazin-6-amine (Compound 4).
[0081] Step 1: To the solution of l-(pyri din-3 -yl)ethanone (3.0 g, 0.024 mol) and (R)-2-methylpropane-2-sulfinamide (6.0 g, 0.048 mol) in anhydrous THF (60 ml) at 0 °C, was added Ti(O‘Pr)4 (10.2 ml, 0.036 mol). The reaction was heated at 60 °C for 24 h. The reaction mixture was poured into crushed ice and extracted with DCM. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was then purified by silica gel chromatography, eluted with a mixture of 50:50 EtOAc and hexane to obtain (R, E)-2-methyl-N-(l-(pyridin-3-yl)ethylidene)propane-2- sulfinamideas a colourless liquid (0.92 g, 34%). Mass: 225 [M+H]+.
[0082] Step 2: To the solution of (E)-2-methyl-N-( l-(pyri din-3 - yl)ethylidene)propane-2-sulfinamide (0.9 g, 0.004 mol) was added DIBAL-H (8 ml , 0.008 mol) at - 78 °C and stirred for 6 h. The reaction mixture was quenched with ammonium chloride and poured over crushed ice followed by extraction with ethyl acetate. The combined organic layer was washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography, eluted withMeOH:DCM (5:95) mixture to obtain (R)-2-methyl-N-((R)-l-(pyri din-3 -yl)ethyl)propane- 2-sulfinamide as a colorless liquid (0.740 g, 81%).1H-NMR (400 MHz, CDCh): 5 (ppm) 8.61 (d, J = 4 Hz, 1H), 8.55 (d, J = 8 Hz, 1H), 7.70-7.67 (m, 1H), 1.30-1.26 (m, 1H ), 4.62- 4.56 (m, 1H) , 3.41 (s, 1H), 1.58 (d, J = 8.4 Hz , 3H), 1.24 (s, 9H).
[0083] Step 3: To the solution of (R)-2-methyl-N-((R)-l-(pyri din-3 - yl)ethyl)propane-2-sulfinamide (0.9 g, 0.002 mol) in DCM (5 ml) was added 4M HC1 in dioxane (15 ml) at 0 °C and stirred at RT for 16 h. The reaction mixture was concentrated and co-precipitated with MeOH: ether as co-solvent to provide (R)-l-(pyridin-3- yl)ethanamine hydrochloride as a white solid (0.51 g, 99.4%). (
[0084] Step 4: To the solution of (R)-l-(pyri din-3 -yl)ethanamine hydrochloride (0.5 g, 0.0032 mol) in DMF (10 ml) in a reaction vessel was added DIPEA (1.67 ml, 0.0096 mol) followed by 6-chloro-3-(trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazine (0.780 g, 0.0035 mol). The reaction mixture was then placed in a seal tube and heated at 80 °C for 16 h. The reaction mixture was diluted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography, eluted with a mixture of (5:95) MeOH:CH2C12 providing (R)-N-(l-(pyri din-3 -yl)ethyl)-3- (trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazin-6-amine as an off colour solid (0. 2 g, 22%).
[0085] 1H -NMR (400 MHz, DMSO-d6): 5 (ppm) 8.61 (d, J = 2 Hz, 1H), 8.43 (d, J = 4.8 Hz, 1H), 8.34 (d , J = 6.8 Hz , 1H), 8.09 (d, J = 10 Hz, 1H), 7.78-7.75 (m ,1H) , 7.35-7.32 (m, 1H), 7.025 (d, J = 12 Hz, 1H) ,4.87-4.84 (m , 1H ), 1.52 (d, J = 6.8 Hz, 3H); Mass: 309.31 [M+H]+; LCMS: 95.34% ; SOR:
[0086] Example 5: Synthesis of (R,S)-6-(l-(4-fluorophenyl)ethoxy)-3- (trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazine (Compound 5)Compound 5
[0087] A mixture of (R,S)-l-(4-fluorophenyl)ethan-l-ol (0.15 g, 1.08mmol) in DMF (3 mL) and potassium carbonate (0.24 g, 1.8 mmol) was stirred at rt for 15 min. 6- chloro-3-(trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazine (0.2 g, 0. 9 mmol) was added and the reaction mixture was heated at 80°C for 16 h. The reaction was then diluted with water (20 mL) and the product extracted into EtOAc. The extract was dried over anhydrous sodium sulphate and concentrated under reduced pressure to give a crude product which was purified by silica gel column chromatography to give (R,S)-6-(l-(4- fhiorophenyl)ethoxy)-3-(trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazine as a white solid (0.15 g, 51% yield).
[0088] 1H-NMR (400 MHz, DMSO-d6): 5 (ppm) 8.44 (d, J = 10.00 Hz, 1H), 7.56-7.53 (m, 2H), 7.31 (d, J = 10.00 Hz, 1H), 7.23-7.18 (m, 2H), 6.03 (q, J = 6.40 Hz, 1H), 1.68 (d, J = 6.80 Hz, 3H); LCMS: (M+H = 327.08).
[0089] Example 6: Synthesis of (R,S)-6-((l-(4-fhiorophenyl)ethyl)thio)-3-(trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazine (Compound 6)
[0090] Step 1: - S-(l-(4-fluorophenyl)ethyl) ethanethioate: To a stirred solution of 1 -(4-fluorophenyl)ethan- 1 -ol (1g, 7.13mmol) and thioacetic acid (1.08g, 14.3mmol) in THF (3 mL) was added triphenylphosphine (3.74g, 14.3mmol) and diisopropyl azodicarboxylate (2.88g, 2.85mmol) at 0°C under argon. After stirring for 3h at RT, the solvent was removed under reduced pressure and the resulting mixture was suspended in n-pentane (20 mL). The suspension was filtered through a bed of celite and the filtrate was concentrated under vacuum to give a crude product that was purified by silica gel column chromatography to give S-(l-(4-fluorophenyl)ethyl) ethanethioate as a pale yellow thick liquid (0.25g, 25% yield).
[0091] Step 2: - (R,S)-6-((l-(4-fhiorophenyl)ethyl)thio)-3-(trifluoromethyl)- [l,2,4]triazolo[4,3-b]pyridazine: The product of step 1 (0.2g, 0.5mmol) was added to a stirred solution of LiAlH4 (0.14g, Immol) in THF at 0 °C. The reaction was allowed to warm up to RT and stirring was continued for a further 2h when 6-chloro-3- (trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazine (0.14g, 0.64mmol) was added. After stirring for a further 3hrs at RT, the reaction mixture was diluted with water and the product extracted into EtOAc. The organic extract was dried over anhydrous sodium sulphate and concentrated under reduced pressure to give a crude product which was purified by silica gel column chromatography to give (R,S)-6-((l-(4-fhiorophenyl)ethyl)thio)-3- (trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazine as colorless sticky solid (40 mg, 18% yield).
[0092] 1H-NMR (400 MHz, DMSO-d6): 5 (ppm) 8.37 (d, J = 9.60 Hz, 1H), 7.58-7.54 (m, 2H), 7.48 (d, J = 9.60 Hz, 1H), 7.17 (t, J = 8.80 Hz, 2H), 5.01 (q, J = 7.20 Hz, 1H), 1.76 (d, J = 7.20 Hz, 3H). LCMS: (M+H = 343.23).
[0093] Example 7: Synthesis of (R)-N-(l-(4-phenoxyphenyl)ethyl)-3- (trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazin-6-amine {Compound 7)
[0094] Step 1: To the solution of 1 -(4-phenoxyphenyl)ethanone (2.0 g, 0.009 mol) and (R)-2-methylpropane-2-sulfinamide (1.36 g, 0.0113 mol) in anhydrous THF (80 ml) at 0 °C was added Ti(O‘Pr)4 (4.1 ml, 0.0141 mol). The reaction was heated at 60 °C for 48 h. The reaction mixture was poured over crushed ice and extracted with DCM. The combined organic layer was washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography, eluted with a mixture of EtOAc:hexanes (50:50) providing (R,£)-2-methyl-N-(l -(4-phenoxyphenyl)ethylidene)propane-2- sulfinamide as a colourless liquid (0.920 g, 28%); Mass: 316 [M+H]+.
[0095] Step 2: To the solution of ((R)-2-methyl-N-(l-(4- phenoxyphenyl)ethylidene)propane-2-sulfinamide (0.9g, 0.004 mol) in THF (10 ml) was added DIBAL-H (8 ml, 0.008 mol) at -78 °C and stirred for 6 h. The reaction mixture was quenched with ammonium chloride, poured over crushed ice and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over Na2SO4, filtered and concentrated. The residue was then purified by silica gel chromatography, eluted with a gradient of 0 to 5% MeOH in DCM providing (R)-2-methyl-N-((R)-l-(4- phenoxyphenyl)ethyl)propane-2-sulfinamide as a colourless liquid (0.9 g, 90%). ;1H - NMR (400 MHz, CDCh): 8 (ppm) 7.36 (m, 4H), 7.11 (s, 1H), 7.02-6.96 (m, 4H), 4.56- 4.51 (m, 1H), 1.50 (d, J = 8 Hz, 3H) ,1.23 (s, 9H).
[0096] Step 3: To the solution of (R)-2-methyl-N-((R)-l-(4- phenoxyphenyl)ethyl)propane-2-sulfinamide (0.9 g, 0.002 mol) in DCM (20 ml) was added 4M HC1 in dioxane (15 ml) at 0 °C and stirred at RT for overnight. The reaction mixture was concentrated and co-precipitated with MeOH:ether as co-solvent to provide (R)-l-(4-phenoxyphenyl)ethanamine hydrochloride as a white solid (0.630 g, 54%).
[0097] Step 4: To the solution of (R )-1 -(4-phenoxyphenyl)ethanamine hydrochloride (0.600 g, 0.0024 mol) in DMF (10 ml) was added DIPEA (0.936 ml, 0.007 mol) followed by addition of 6-chloro-3-(trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazine (0.590 g, 0.003 mol). The reaction was heated at 80 °C for 16 h. The reaction mixture was diluted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography, eluted with a gradient of 0 to 5% MeOH in DCM providing (R)-N-(l-(4-phenoxyphenyl)ethyl)-3-(trifluoromethyl)- [l,2,4]triazolo[4,3-b]pyridazin-6-amine as a cream coloured solid (0. 07 g, 8%).
[0098] 1H-NMR (400 MHz, DMSO-d6): 5 (ppm) 8.23 (d, J = 7.2 Hz, 1H), 8.08 (d,J = 10 Hz, 1H), 7.41-7.35 (m, 4H), 7.12 (t, J = 7.2 Hz, 1H), 7.03 (d, J = 10 Hz ,1H), 6.97- 6.94 (m, 4H), 4.88-4.81 (m, 1H) ,1.51 (d, J = 6.8 Hz, 3H); Mass: 400.39 [M+H]+. LCMS:
[0099] Example 8: Synthesis of (R)-N-(l-(4-fhiorophenyl)ethyl)-3- (trifluoromethyl)-7,8-dihydro-[l ,2,4]triazolo[4,3-b]pyridazin-6-amine (Compound 8)
[0100] Step 1 : To the solution of (6-chloro-3-trifluoromethyl-[l,2,4]triazolo[4,3- b]pyridazine) (11.00 g, 0.049 mol) in DMF (220 ml) was added DIPEA (19 ml, 0.1486 mol) followed (R)-l-(4-fhiorophenyl)ethanamine (7.23 g, 0.052 mol). The reaction mixturewas placed in a seal tube and heated at 90 °C for 16 h. The reaction was diluted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography, eluted with a gradient of 0 to 5% MeOH in DCM providing (R )-N-(l-(4-fhiorophenyl)ethyl)-3-(trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazin-6- amine as a cream coloured solid (7.76 g, 47%). ;
[01011] H -NMR (400 MHz, DMSO-d6): 5 (ppm) 8.26 (d, J = 8 Hz, 1H), 8.08 (d, J = 8 Hz, 1H), 7.44-7.40 (m, 2H), 7.16-7.11 (m, 2H), 7.02 (d, J = 8 Hz 1H), 4.85-4.80 (m, 1H), 1.50 (d, J = 8 Hz, 3H); Mass: 326 [M+H]+; SOR: [a]xT= + 303.16.
[0102] Step 2: To the solution of (R)-N-(l-(4-fhiorophenyl)ethyl)-3- (trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazin-6-amine (0.250 g, 0.76 mol) in MeOH (5 ml) in a reaction vial was added Pd / C (0.25 g) and reaction was stirred in hydrogen atmosphere for 16 h. Reaction mixture was filtered through celite to get the crude compound. The crude was then purified by silica gel chromatography, eluted with a gradient of 0 to 5% MeOH in DCM providing (R)-N-(l-(4-fhiorophenyl)ethyl)-3- (trifluoromethyl)-7,8-dihydro-[l,2,4]triazolo[4,3-b]pyridazin-6-amine as an off-white colour solid (0.2 g, 80%).
[0103] 1H-NMR (400 MHz, DMSO-d6): 5 (ppm) 7.96 (d, J = 6.8 Hz, 1H), 7.39- 7.35 (m, 2H), 7.15-7.11 (m, 2H), 4.87-4.84 (m, 1H), 3.08-3.04 (m, 2H), 2.73-2.66 (m, 2H), 1.43 (d, J = 7.2 Hz, 3H); Mass: 328.25 [M+H]+; LCMS: 99.17%; SOR:Synthesis of compounds of Series B
[0104] Example 9: N-(l-(3-(pyrrolidin-l-yl)phenyl)ethyl)-3-(trifluoromethyl)- [l,2,4]triazolo[4,3-b]pyridazin-6-amine (Compound 9)
[0105] Step 1: N-(l-(3-bromophenyl)ethyl)-3-(trifluoromethyl)-[ 1 ,2,4]triazolo[4,3 -b]pyridazin-6-amine
[0106] A stirred solution of 6-chloro-3-(trifluoromethyl)-[l,2,4]triazolo[4,3- b]pyridazine (0.3 g, 1.347 mmol), DMF (4 mL), l-(3-bromophenyl)ethan-l -amine (0.27 g, 1.347 mmol) and DIPEA (3.37 mL, 4.043 mmol) was heated at 90°C for 5h. The reaction mixture was evaporated to dryness and, after an aqueous / ethyl acetate extraction work up, the crude product was purified by column chromatography to give N-(l-(3- bromophenyl)ethyl)-3-(trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazin-6-amine an off- white solid (0.35g, 67%).
[0107] Step 2: N-(l-(3-(pyrrolidin-l-yl)phenyl)ethyl)-3-(trifluoromethyl)- [ 1 ,2,4]triazolo[4,3 -b]pyridazin-6-amine
[0108] A suspension of the product of Step 1 (0.15 g, 0.39 mmol), cesium carbonate(0.38 g, 1.17 mmol) in 1,4-di oxane (5 mL) and pyrrolidine (0.16 mL), 1.9 mmol) was purged with Argon gas for 15 minutes. After adding Pd(OAc)2 (9 mg, 0.034 mmol) and X- Phos (37 mg, 0.078 mmol), the reaction mass was irradiated by microwave at lOOoC for Ih. The reaction mass was diluted with water (7 mL) and after an aqueous / ethyl acetate extraction work up, the crude product was purified by column chromatography (Davisil ) using 5% methanol in DCM to give N-(l-(3-(pyrrolidin-l-yl)phenyl)ethyl)-3- (trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazin-6-amine (50mg, 47%).
[0109] ' H-NMR (400 MHz, DMSO-d6): 5 (ppm) 8.16 (d, J = 7.60 Hz, IH), 8.06 (d, J = 10.00 Hz, IH), 7.10 (t, J = 7.60 Hz, IH), 7.02 (d, J = 10.00 Hz, IH), 6.63 (d, J = 7.60 Hz, IH), 6.56 (s, IH), 6.39 (dd, J = 1.60, 8.00 Hz, IH), 4.84-4.75 (m, IH), 3.19 (t, J= 6.40 Hz, 4H), 1.93 (t, J = 6.40 Hz, 4H), 1.48 (d, J = 6.80 Hz, 3H). LCMS: 99.05 % (m / z= 377.25 [M+H]+)
[0110] Example 10: Synthesis of N-(l-(4-(lH-benzo[d]imidazol-l- yl)phenyl)ethyl)-3-(trifluoromethyl)-[ 1 ,2,4]triazolo[4,3-b]pyridazin-6-amine {Compound 10)
[0111] A solution of l-(4-(lH-benzo[d]imidazol-l-yl)phenyl)ethan-l-amine (70mg, 0.3mmol) and 6-chloro-3-(trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazine (66mg, 0.3mmol) in DMF (0.7mL) and DIPEA (0.15mL, 0.9mmol) was stirred at 80°C for 4h. The reaction was cooled and, after an aqueous / organic work up, purified by column chromatography to give N-(l-(4-(lH-benzo[d]imidazol-l-yl)phenyl)ethyl)-3- (trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazin-6-amine off-white solid (22mg, 19% yield.
[0112] 1H-NMR (400 MHz, DMSO-d6): 5 8.51 (s, 1H), 8.38 (d, J = 6.80 Hz, 1H), 8.11 (d, J = 10.00 Hz, 1H), 7.76 (dd, J = 2.00, 6.20 Hz, 1H), 7.64 (s, 4H), 7.58-7.56 (m, 1H), 7.35-7.25 (m, 2H), 7.07 (d, J = 10.00 Hz, 1H), 4.96 (t, J = 6.80 Hz, 1H), 1.58 (d, J = 6.80 Hz, 3H). LCMS: 99.68 %, m / z = 424.37 [M+H]))
[0113] Synthesis of compounds of Series C
[0114] Example 11: Synthesis of N-(l-(3-fhioro-4-(2-methyl-lH-imidazol-l- yl)phenyl)ethyl)-1H-[l,2,3]triazolo[4,5-b]pyridin-5-amine {Compound 11)
[0115] To a stirred solution of N6-(l-(3-fhioro-4-(2-methyl-lH-imidazol-l- yl)phenyl)ethyl)pyridine-2,3,6-triamine (0.16 g, 0.49 mmol) in a mixture of glacial acetic acid (0.4 mg, 0.008 mmol) and water (1.0 mL) at 5°C, was added a solution of sodium nitrite (51 mg, 0.73 mmol) in 1.5 mL of water. After 6hrs at RT, the reaction mass was diluted with ethyl acetate and the organic layer was washed with saturated NaHCO3 solution, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude was purified by column chromatography to give N-(l -(3 -fhioro-4-(2 -methyl - lH-imidazol-l-yl)phenyl)ethyl)-lH-[l,2,3]triazolo[4,5-b]pyridin-5-amine as a white solid (18 mg, 11% yield).
[0116] 1H -NMR (400 MHz, DMSO-d6): 5 (ppm) 15.25 (s, 1H), 7.99 (d, J = 8.80 Hz, 1H), 7.87 (d, J = 7.20 Hz, 1H), 7.36-7.35 (m, 3H), 7.21 (s, 1H), 6.91 (d, J = 1.60 Hz, 1H), 6.72 (d, J = 8.80 Hz, 1H), 5.24 (t, J = 7.20 Hz, 1H), 2.15 (s, 3H), 2.15 (d, J = 6.80 Hz, 3H). LCMS: 99.63% (m / z = 338.30 [M+H]+).
[0117] Example 12: Synthesis of N-(l-(3-fhioro-4-(2-methyl-lH-imidazol-l- yl)phenyl)ethyl)-lH-imidazo[4,5-b]pyridin-5-amine (Compound 12)
[0118] Step 1: N2-(l-(3-fluoro-4-(2-methyl-lH-imidazol-l-yl)phenyl)ethyl)-5- nitropyridine-2,6-diamine
[0119] A stirred solution of 6-chloro-3-nitropyridin-2-amine, DIPEA (3mL) and 1 - (3-fluoro-4-(2-methyl-lH-imidazol-l-yl)phenyl)ethan-l -amine (1.51g, 6.9mmol) in DMF (lOmL), was heated at 80°C for 16h. The reaction mixture was diluted with ice-cold water and after an aqueous / ethyl acetate extraction work up, the crude product was purified by column chromatography to give N2-(l -(3 -fluoro-4-(2 -methyl- 1H-
[0120] Step 2: N6-(l-(3-fhioro-4-(2-methyl-lH-imidazol-l- yl)phenyl)ethyl)pyridine-2,3,6-triamine
[0121] A stirred solution of the product of Step 1 and tin(II) chloride dihydrate in ethyl acetate (2.8mL) was stirred at 60°C for 6 h. The reaction mass was cooled, filtered through a celite bed and washed with sat. NaHCO3 solution, dried over Na2SO4 and concentrated to give a crude product (0.2g, 55%).
[0122] Step 3: N-(l-(3-fhioro-4-(2-methyl-lH-imidazol-l-yl)phenyl)ethyl)-lH- imidazo[4,5-b]pyridin-5-amine
[0123] Triethyl orthoformate (132 mL) was added to a stirred solution of the product of Step 2 (6.53g, 26.3mmol) in formic acid (28mL) at 0°C. Reaction mixture was heated to 80°C for 3 hours. The reaction mixture was evaporated to dryness under reduced pressure and the crude product was purified by flash column chromatography (Davisil), eluted with 8% methanol in DCM to give N-(l-(3-fhioro-4-(2-methyl-lH-imidazol-l- yl)phenyl)ethyl)-lH-imidazo[4,5-b]pyridin-5-amine as white solid (0.042g).
[0124] 1H-NMR (400 MHz, DMSO-d6): 5 (ppm) 7.83 (s, 1H), 7.67 (d, J = 8.40 Hz,1H), 7.42-7.44 (m, 3H), 7.21 (s, 1H), 7.12 (d, J = 7.60 Hz, 1H), 6.90 (d, J = 1.20 Hz, 1H), 6.50 (d, J = 8.80 Hz, 1H), 5.15 (t, J = 7.20 Hz, 1H), 0.00 (s, 3H), 0.00 (d, J = 6.80 Hz, 3H). LCMS: 99.5 % (m / z = 406.31 [M+H]+ion present)
[0125] Example 13: Synthesis of N-(l-(3-fhioro-4-(2-methyl-lH-imidazol-l- yl)phenyl)ethyl)-lH-pyrrolo[2,3-b]pyridin-6-amine (Compound 13)Compound 13
[0126] Step 1: 6-bromo-l -(triisopropylsilyl)- lH-pyrrolo[2,3-b]pyridine
[0127] A stirred solution of 6-bromo-lH-pyrrolo[2,3-b]pyridine (0.5 g, 2.53 mmol), DIPEA (1.36 g, 7.63 mmol) and triisopropylsilyl trifluoromethanesulfonate (1.94 g, 6.91 mmol) in 1,4-dioxane was heated at 80°C for 16h. The reaction was diluted with ethyl acetate, washed with saturated NaHCO, and brine, dried over Na2SO4, and concentrated under reduced pressure to give a crude product which was purified by column chromatography to give 6-bromo-l -(triisopropylsilyl)- lH-pyrrolo[2,3-b]pyridine 3 as a yellow oil (0.6g, 67%).
[0128] Step 2: N-(l-(3-fhioro-4-(2-methyl-lH-imidazol-l-yl)phenyl)ethyl)-l-(triisopropylsilyl)-lH-pyrrolo[2,3-b]pyridin-6-amine
[0129] A suspension of 1 -(3 -fluoro-4-(2 -methyl- IH-imidazol-l -yl)phenyl)ethan- 1-amine (0.3 g, 1.36 mmol), the product of Step 1 (0.48 g, 2.53 mmol) and cesium carbonate (1.34 g, 4.10 mmol) in dioxane was purged with nitrogen gas for 5 minutes. After adding Pd2(dba)s (60 mg, 0.068 mmol) and racemic BINAP (64 mg, 0.103 mmol) the tube was sealed and the reaction mass was heated at 120°C for 1 h. The reaction mixture was filtered through celite, concentrated under reduced pressure and after an aqueous / ethylacetate extraction work up, the crude product was purified by silica gel column chromatography to give N-(l-(3-fluoro-4-(2-methyl-lH-imidazol-l-yl)phenyl)ethyl)-l- (triisopropylsilyl)-lH-pyrrolo[2,3-b]pyridin-6-amine as a brown gum (0.2g, 29%).
[0130] Step 3: N-(l-(3-fluoro-4-(2-methyl-lH-imidazol-l-yl)phenyl)ethyl)-lH- pyrrolo[2,3-b]pyridin-6-amine
[0131] A stirred solution of the product of Step 2 (0.2 g, 0.47 mmol) and TBAF (0.47 g, 0.47 mmol) in THF (5 mL), was stirred at rt for 4h. The reaction was diluted with DCM and the organic layer was washed with saturated aqueous NH4C1, dried over sodium sulfate, and evaporated to get crude product which was purified by column chromatography (Silica 100-200 mesh) to give N-(l-(3-fhioro-4-(2-methyl-lH-imidazol-l- yl)phenyl)ethyl)-lH-pyrrolo[2,3-b]pyridin-6-amine as white solid (0.02g, 15%).
[0132] 1H -NMR (400 MHz, DMSO-d6): 5 (ppm) 10.88 (s, 1H), 7.56 (d, J = 8.40 Hz, 1H), 7.48 (d, J = 1.20 Hz, 1H), 7.43 (t, J = 7.60 Hz, 1H), 7.38 (dd, J = 1.60, 8.20 Hz, 1H), 7.21 (s, 1H), 6.87-6.85 (m, 3H), 6.37 (d, J = 8.40 Hz, 1H), 6.15-6.14 (m, 1H), 6.13 (t, J = 7.20 Hz, 1H), 2.14 (s, 3H), 1.48 (d, J = 7.20 Hz, 3H). LCMS: 97.95% (m / z = 336.29 [M+H] +).
[0133] Example 14: Synthesis of (R)-N-(l-(3-fhioro-4-(2-methyl-lH-imidazol-l- yl)phenyl)ethyl)tetrazolo[l,5-b]pyridazin-6-amine {Compound 14)
[0134] Step- 1 : 1 -(3 -fluoro-4-(2 -methyl- 1 H-imidazol- 1 -yl)phenyl)ethan- 1 -one
[0135] To the stirred solution of l-(3,4-difluorophenyl)ethan-l-one (4.0 g, 0.256 mol, 1.0 eq ) in DMSO (40 ml) was added K2CO3 (4.8 g, 0.033mol, 1.3 eq) followed by 2- methyl-lH-imidazole (2.8 g, 0.033 mol, 1.3 eq). The reaction mixture was heated at 80°C for 16 hours. The reaction mixture was diluted with EtOAc and washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give l-(3-fhioro-4-(2-methyl-lH-imidazol-l- yl)phenyl)ethan-l-one as a brown solid (3.6 g, 64%).
[0136] 1H-NMR (400 MHz, CDCh): 8 (ppm) 7.87-7.86 (m, 1H), 7.85-7.83 (m, 1H), 7.43 (t, J=12Hz, 1H), 7.09 (d, J=4Hz, 1H), 6.98 (d, J=4hz, 1H), 2.65 (s, 3H), 2.33 (s, 3H).
[0137] Step-2: N-((R)- 1 -(3-fluoro-4-(2 -methyl- 1 H-imidazol- 1 -yl)phenyl)ethyl)-2- methylpropane-2-sulfinamide
[0138] To the solution of l-(3-fluoro-4-(2 -methyl- IH-imidazol-l -yl)phenyl)ethan-1-one (1.6 g, 0.0073 mol, 1.0 eq) and (R)-2-methylpropane-2-sulfinamide (1.78 g, 0.0147 mol, 2.0 eq) in anhydrous THF (30mL) at 0 °C, was added Ti(iOPr)4 (2.51 g, 0.0110 mol, 1.5 eq). The reaction was heated at 60 °C for 16 h. The reaction was cooled to -50 °C and NaBEU (0.83 g, 0.022 mol, 3.0 eq) was added and allowed to stir overnight at room temp. The reaction was poured over crushed ice and aqueous layer was extracted with EtOAc. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel chromatography to give N-((R)-l-(3- fluoro-4-(2-methyl-lH-imidazol-l-yl)phenyl)ethyl)-2-methylpropane-2-sulfinamide as a white solid (2.0 g, 84%).
[0139] Step-3 : (R)- 1 -(3 -fluoro-4-(2 -methyl- 1 H-imidazol- 1 -yl)phenyl)ethan- 1 - amine hydrochloride
[0140] To the solution of N-((R)-1 -(3 -fhioro-4-(2-methyl- 1 H-imidazol- 1- yl)phenyl)ethyl)-2-methylpropane-2-sulfinamide (1.0 g, 0.003 mol, 1.0 eq) in DCM (40 ml) in a reaction vial was added 4M HC1 in dioxane (5 ml) at 0 °C and stirred at rt for overnight. The reaction was concentrated and co-precipitated with MeOH: ether as cosolvent to provide (R)-l-(3-fhioro-4-(2-methyl-l H-imidazol- 1 -yl)phenyl)ethan- 1 -amine hydrochloride as a white solid (0.6g, 89%).
[0141] 1H-NMR (400 MHz, DMSO-d6): 5 (ppm) 8.84 (bd, 3H), 7.92-7.82 (m, 4H),7.66 (d, J=8Hz, 1H), 4.57 (m, 1H), 1.57 (d, J=8Hz, 3H).
[0142] Step-4: (R)-N-( 1 -(3 -fluoro-4-(2 -methyl- 1 H-imidazol- 1- yl)phenyl)ethyl)tetrazolo[l,5-b]pyridazin-6-amine
[0143] To the solution of 6-chlorotetrazolo[l,5-b]pyridazine (0.42 g, 0.0027, 1.1 eq) in DMF (10 ml) in a reaction vial was added DIPEA (1.8 ml, 0.0081 mol, 3 eq) followed by (R)- 1 -(3-fluoro-4-(2 -methyl- 1 H-imidazol- 1 -yl)phenyl)ethan- 1 -amine hydrochloride (0.6 g, 0.002, 1.0 eq). The reaction mixture was heated at 90 °C for 16 h. The reaction was diluted with EtOAc and washed with brine, dried over Na2SO4, filtered, and concentrated.The residue was purified by silica gel chromatography, to give ((R)-N-(l-(3-fluoro-4-(2- methyl-lH-imidazol-l-yl)phenyl)ethyl)tetrazolo[l,5-b]pyridazin-6-amine as a yellow solid (0.22 g, 27%).
[01441] H -NMR (400 MHz, DMSO-d6): 5(ppm) 8.45 (d, J=8Hz, 1H), 8.26 (d, J=12Hz, 1H), 7.56-7.49 (m, 2H), 7.42 (d, J=8Hz, 1H) 7.24 (d, J=8Hz, 2H), 6.92 (d, J=4Hz, 1H), 5.15-5.11 (m, 1H), 2.15 (s, 3H), 1.55 (d, J=4Hz, 3H; LCMS = 338.97 [M+H]+HPLC = 97.29; SOR:
[0145] Example 15: Synthesis of (S)-N-(l-(3-fhioro-4-(2-methyl-lH-imidazol-l- yl)phenyl)ethyl)tetrazolo[l,5-b]pyridazin-6-amine( Compound 15)Compound 15
[0146] Compound 15 was prepared in a similar fashion as Example 14 to provide (S)-N-(l -(3-fluoro-4-(2 -methyl- 1 H-imidazol- 1 -yl)phenyl)ethyl)tetrazolo[ 1 ,5-b]pyridazin- 6-amine (0.1g, 32% yield).
[0147] 1H-NMR (400 MHz, DMSO-d6): 5 (ppm) 8.44 (d, J=8Hz, 1H), 8.28 (d, J=12Hz, 1H), 7.56-7.49 (m, 2H), 7.42 (d, J=8Hz, 1H), 7.24 (d, J=8Hz, 1H), 6.9 (s, 1H). 5.15-5.11 (m, 1H), 2.15 (s, 3H), 1.55 (d, J=4Hz, 3H); Mass: 337.03 [M-H]+; HPLC: 97.64; SOR:
[0148] Example 16: Synthesis of (R)-N-(l-(3-fhioro-4-(2-(trifluoromethyl)-lH- imidazol-l-yl)phenyl)ethyl)tetrazolo[l,5-b]pyridazin-6-amine {Compound 16)
[0149] Step 1: 2-(Trifluoromethyl)-lH-imidazole (1.0 g, 0.0073 mol) in DMSO (20 mL) was taken in a sealed tube followed by 1 -(3,4-difluorophenyl)ethanone (1.26 g, 0.0080 mol) and K2CO3 (2.01 g, 0.0146 mol) was added. The reaction mixture was heated at 80°C for 16 h. The reaction mass was dissolved in EtOAc and washed with brine solution. The organic layer was separated, and the aqueous layer was extracted two times with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to obtain l-(3-fhioro-4-(2-(trifhioromethyl)-lH- imidazol-l-yl)phenyl)ethanone as an off white solid (1.31 g, 77%). .1H-NMR (400 MHz, DMSO-d6): 5 (ppm) 8.07-8.03 (dd, J = 4 Hz, 12 Hz, 1H), 7.98-7.96 (dd, J = 4 Hz, 8 Hz, 1H), 7.87-7.82 (m, 2H), 7.38(s, 1H), 2.67 (s, 3H).
[0150] Step 2: To the solution of l-(3-fhioro-4-(2-(trifluoromethyl)-lH-imidazol- 1 -yl)phenyl)ethanone (1.3 g, 0.0047 mol) and (R)-2-methylpropane-2-sulfinamide (1.04 g, 0.0086 mol) in anhydrous THF (30 ml) at 0 °C was added Ti(O‘Pr)4 (5.9 ml, 0.0188). The reaction mixture was heated at 60 °C for 16 h. The reaction was cooled to -78 °C and NaBH4 (0.715 g, 0.0188 mol) was added and allowed to stir for overnight at room temp. The reaction mixture was poured into crushed ice and extracted with EtOAc. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated. Theresidue was purified by silica gel chromatography, eluted with a gradient of 0 to 50% EtOAc in hexanes providing (R )-N-((R )-l-(3-fluoro-4-(2-(trifluoromethyl)-lH-imidazol- l-yl)phenyl)ethyl)-2-methylpropane-2-sulfinamide as a colourless liquid (0.8 g, 44%). ;1H-NMR (400 MHz, DMSO-d6): 8 (ppm) 7.75 (d, J = 4 Hz, 1H), 7.62-7.55 (m, 2H), 7.44- 7.41(d, J =4 Hz , 8 Hz, 1H), 7.33 (d, J = 4 Hz , 1H), 5.90 (d, J= 8 Hz ,1H), 5.75 (s, 1H), 4.52-4.49 (m, 1H), 1.43 (d , J = 8 Hz, 3H) ,1.14 (s , 9H).
[0151] Step 3: To the solution of (R)-N-((R)-l-(3-fhioro-4-(2-(trifhioromethyl)- lH-imidazol-l-yl)phenyl)ethyl)-2-methylpropane-2-sulfinamide (0.8 g, 0.0021 mol) in DCM (20 ml) was added 4M HC1 in dioxane (5 ml) at 0 °C and stirred at RT for 16 h. The reaction mixture was concentrated and co-precipitated with a mixture of solvents MeOH and ether to provide (R)-1-(3-fluoro-4-(2-(trifluoromethyl)-lH-imidazol-l- yl)phenyl)ethanamine hydrochloride as a white solid (0.670 g, 99%). .
[0152] Step 4: To the solution of (R)-1-(3-fhioro-4-(2-(trifluoromethyl)-lH- imidazol-l-yl)phenyl)ethanamine hydrochloride (0.670 g, 0.0025 mol) in DMF (10 ml) was added DIPEA (1.3 ml, 0.0073 mol) followed by 6-chlorotetrazolo[l,5-b]pyridazine (0.418 g, 0.00269 mol). The reaction was heated in a seal tube at 90 °C for 16 h. The reaction was diluted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography, eluted with a gradient of 0 to 5% MeOH in DCM providing (R)-N-(1-(4-fluorophenyl)propyl)-3- (trifluoromethyl)-[l,2,4]triazolo[4,3-b]pyridazin-6-amine as an off-white colour solid (0. 38 g, 39%). / ;1H-NMR (400 MHz, DMSO-d6): 8 (ppm) 8.47 (d, J = 7.2 Hz, 1H), 8.29 (d, J = 9.6 Hz, 1H), 7.75 (s ,1H) 7.65-7.57 (m, 2H), 7.45 (d, J = 8 Hz, 1H), 7.31 (s, 1H), 7.25 (d, J = 10 Hz, 1H), 5.16-5.13 (m, 1H), 1.56 (d, J = 6.8 Hz, 3H); Mass: 393.39 [M+H]+; LCMS: 95.32%. SOR:Biological Studies
[0153] Indigo Biosciences Discovery Assay
[0154] The aim of this study was to evaluate compounds of the present inventionfor antagonist activities against human AR. Reporter Cells used in these assays expressed a native receptor (AR). The reporter gene, firefly luciferase, is functionally linked to an upstream receptor-specific genetic response element (GRE). Reporter cells were treated with eight concentrations, starting at 50 uM and following with 3.17-fold dilutions. Single treatment concentration was performed (n=l). Assay performance was validated using the reference antagonist hydroxy flutamide
[0155] Step 1: A suspension of reporter cells was prepared in Cell Recovery Medium (CRM). Reporter cells were first supplemented with 2x-EC80 concentration of the reference agonist, 5oc-dihydro-l 1-keto testosterone, then 100 ul of the Reporter Cell suspension was dispensed into wells of a white 96-well assay plate
[0156] Step 2: Test compound master stocks were diluted in DMSO to generate solutions at '500x-concentration' relative to the final treatment concentration and diluted directly into ENDlGO’s Compound Screening Medium (CSM; containing charcoalstripped FBS) to generate ‘2x-concentration’ treatment media. This was diluted into the wells to the final concentration. Assay plates were incubated at 37°C, 5% CO2 and -70% humidity for 24 hr.
[0157] Step 3: Following the incubation period, wells were rinsed once with Live Cell Multiplex (LCM) Buffer, then LCM substrate was added. Following incubation at room temperature for 15 min, LCM substrate was discarded and 100 pL / wcll of luciferase detection reagent was added. Subsequently, fluorescence was measured to determine the relative number of live cells per assay well. RLU values were quantified after a 10 min incubation period at room temperature to determine nuclear receptor activitiesMouse / Human Liver Microsome Stability
[0158] Procedure SummaryAssay Procedure
[0159] Preincubation mixture 2.5 pL Test Cpd. + 75 pL Liver microsomes (human or mouse source) @ 3.33 mg / mL + 85 pL of 100 mM potassium phosphate buffer (preincubate for 10 min @ 37°C). Incubation mixture 62 pL of cofactor (2.85 mM) + Remaining incubation mixture (Incubated for 60 min @ 37 °C). Sample preparation 25 pL incubation mixture + 200 pL of acetonitrile containing internal standard + Vortex 5 min @ 1200 rpm + Centrifuge 10 min @ 4000 rpm. Supernatant diluted 2-fold with water and injected on LC-MS / MS.
[0160] Table 1 shows the AR antagonist indigo cell based average IC50 (nM) values for example compounds of the present invention.Table 1 IC50 (nM) values for compounds of the present invention
[0161] T able 2 shows the in vitro microsome stability data for example compounds of the present descriptionTable 2 In vitro microsome stability data
[0162] While only certain features of several embodiments have been illustrated and described herein, many modifications and changes will occur to those skilled in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the scope of the invention and the appended claims.
Claims
CLAIMS1. A compound having a formula (I) or (II) or a pharmaceutically acceptable salt thereof:wherein dotted line “ - ” is a single bond or a double bond;“n” is an integer from 0 to 5 ; “p” is an integer from 0 to 4;A is a C3-C9 cycloalkyl group, a C3-C12 heterocycloalkyl group, a C6-C12 aryl group, or a C3-C12 heteroaryl group;X1, X3, X4and X5are independently at each occurrence nitrogen, NH, CH or CH2;X2is independently at each occurrence carbon or nitrogen; wherein in formula (I) at least one of X1, X2, X3, X4and X5is carbon, CH or CH2 and at least two of X1, X2, X3, X4and X5are nitrogen or NH, and in formula (II) at least two of X1, X2, X3, X4and X5are nitrogen or NH;Y is O, S, or NR6;R1is a C1-C6alkyl group optionally substituted with one or more fluorine or deuterium or a C3-C7cycloalkyl group optionally substituted with one or more fluorine or deuterium;R2is a C1-C6alkyl group optionally substituted with one or more fluorine, a C3-C7cycloalkyl group optionally substituted with one or more fluorine, — OR7, or SF5;R3is independently at each occurrence halogen, — CN, — OR7, — NHC(=O)R7, — C(-C6H5)R7R8, C(=O)NR7R8, NR7R8, P(=O)R7R8, a C1-C6alkyl group optionally substituted with one or more fluorine or deuterium, a C3-C7cycloalkyl group optionally substituted with one or more fluorine or deuterium, a C1-C12heterocycloalkyl group optionally substituted with one or more R9, or a C1-C12heteroaryl group optionally substituted with one or more R9;R4is independently at each occurrence halogen, — CN, — OR7, — NHC(=O)R7, — C(=O)NR7R8, — NR7RS, — P(=O)R7R8, a C1-C6alkyl group optionally substituted with one or more fluorine or deuterium, or a C3-C7cycloalkyl group optionally substituted with one or more fluorine or deuterium;R5is a C1-C12heterocycloalkyl group or a C1-C12heteroaryl group optionally substituted with one or more R9;R6is hydrogen, a C1-C6alkyl group, or a C3-C7cycloalkyl group;R7and R8are independently at each occurrence hydrogen, a C1-C6alkyl group optionally substituted with one or more fluorine or an aminoalkyl group, a Ce-Cio aryl group optionally substituted with one or more fluorine, or R7and R8together with the carbon or nitrogen to which each is attached form a C3-C7cycloalkyl optionally substituted with one or more fluorine or a C3-C15 heterocycloalkyl group optionally substituted with one or more fluorine; andR9is independently at each occurrence halogen, — CN, — OR7, — NHC(=O)R7, — C(=O)NR7R8, NR7R8, a C1-C6alkyl group optionally substituted with one or more fluorine or a C3-C7cycloalkyl group optionally substituted with one or more fluorine;with the proviso that if in formula (I), A is an aryl group, Y is NH, X1, X2, X3and X4, are all nitrogen, R1is a C1-C6alkyl group, R2is a C1-C6alkyl group optionally substituted with one or more fluorine, n is 1, then R3is not a halogen.
2. The compound of claim 1 selected from the group consisting of:and any pharmaceutically acceptable salts thereof.
3. The compound of claim 1, wherein Y is O, S, or NR6, R1is a C1-C3 alkyl group optionally substituted with one or more fluorine, R2is a C1-C3 alkyl group substituted with one or more fluorine, and R6is hydrogen, a C1-C6alkyl group, or a C3-C7cycloalkyl group.
4. The compound of claim 1, wherein Y is O, S, or NR6, R1is a C1-C3 alkyl group optionally substituted with one or more fluorine, R2is a C1-C3 alkyl group substituted with one or more fluorine, R3is independently at each occurrence halogen, — CN, — OR7, or a C1-C3 alkyl group substituted with one or more fluorine, and R6is hydrogen, a Ci-Ce alkyl group, or a C3-C7cycloalkyl group.
5. The compound of claim 1, wherein Y is O, S, or NR6, R1is a C1-C3 alkyl group optionally substituted with one or more fluorine, R2is a C1-C3 alkyl group substituted with one or more fluorine, R3is independently at each occurrence a C1-C3 alkyl groupsubstituted with one or more fluorine, and R6is hydrogen, a C1-C6alkyl group, or a C3-C7cycloalkyl group.
6. The compound of claim 1, wherein Y is NR6, R1is a C1-C3 alkyl group optionally substituted with one or more fluorine, R2is a C1-C3 alkyl group substituted with one or more fluorine, R3is independently at each occurrence a C1-C3 alkyl group substituted with one or more fluorine, and R6is a C1-C3 alkyl group.
7. The compound of claim 1 selected from the consisting of:
8. The compound of claim 1 having a formula (XXI) or any pharmaceutically acceptable salts thereof:(XXI)wherein “n” is an integer from 1 to 5, and at least one R3is a C1-C 1heterocycloalkyl group optionally substituted with one or more R9or a C1-C12heteroaryl group optionally substituted with one or more R9.
9. The compound of claim 8 selected from the group consisting of:any pharmaceutically acceptable salts thereof, wherein “q” is an integer from 0 to 4;“r” is an integer from 0 to 4, and “s” is an integer from 0 to 3.
10. The compound of claim 9, wherein R1is a C1-C3 alkyl group optionally substituted with one or more fluorine, R2is a C1-C3 alkyl group substituted with one or more fluorine, and R6is hydrogen.
11. The compound of claim selected from the group consisting of:
12. The compound of claim 1 having a formula (II) selected from the group consisting of:and any pharmaceutically acceptable salts thereof.
13. The compound of claim 12, wherein R5is selected from the group consistingwherein R9is halogen or a C1-C3 alkyl group optionally substituted with one or more fluorine.
14. The compound of claim 12, wherein Y is O, S, or NR6, R1is a C1-C3 alkyl group optionally substituted with one or more fluorine, R4is independently at each occurrence halogen, and R6is hydrogen, a C1-C6alkyl group, or a C3-C7cycloalkyl group.
15. The compound of claim 12, wherein Y is NR6, R1is a C1-C3 alkyl group optionally substituted with one or more fluorine, R4is independently at each occurrence halogen, and R6is a C1-C3 alkyl group.
16. The compound of claim 12 selected from the group consisting of:and any pharmaceutically acceptable salts thereof.
17. A pharmaceutical composition comprising: the compound of claim 1 or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, or co-crystal thereof, and a pharmaceutically carrier, diluent, or excipient.
18. A method for modulation of androgen receptor activity for treatment of prostate cancer, breast cancer, ovarian cancer, or melanoma, the method comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition comprising a compound of claim 1.
19. The method of claim 18, wherein the method comprises modulation of androgen receptor activity for treatment of metastatic castration-resistant prostate cancer.
20. The method of claim 19, wherein the method comprises modulation of N- terminal domain of an androgen receptor for treatment of metastatic castration-resistant prostate cancer.
Citation Information
Patent Citations
Tetrahydrocarbazole derivatives useful as androgen receptor modulators
US20100022550A1
New analogs as androgen receptor and glucocorticoid receptor modulators
US20200325123A1
